Consensus Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Real-time Estimate Cboe BZX Other stock markets 12:35:44 2024-05-06 EDT			5-day change	1st Jan Change
0.402 ^USD	-2.31%		-11.64%	-27.81%

02-29	Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
01-22	Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	CI

Evolution of the average Target Price on Virios Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

44392b11ec83b105122a9c26be.-dUzFPyioY-7eMGgJ08Yc2lxovHtV5gSkdPkZoSXqI4.vL5dYbDMw-vtNLDtcR56RhMa7pi3LfMgov6iPuXU-MuR5Xt8xOnq_vcdiA~31218b29e6498b7e9e701149f703630c

Analyst Recommendations on Virios Therapeutics, Inc.

US Futures Lower as Investors Gird for Another Fed Rate Increase	22-09-20	MT
HC Wainwright Downgrades Virios Therapeutics to Neutral From Buy	22-09-20	MT
HC Wainwright Starts Virios Therapeutics at Buy With $12 Price Target	21-12-15	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.4115 USD

Average target price

2.2 USD

Spread / Average Target

+434.63%

High Price Target

4 USD

Spread / Highest target

+872.05%

Low Price Target

0.4 USD

Spread / Lowest Target

-2.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Virios Therapeutics, Inc.

HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar